Beam Therapeutics Inc. Operating Lease Cost
Beam Therapeutics Inc. (BEAM) reported Operating Lease Cost of $21.31 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-24
- Beam Therapeutics Inc. operating lease, cost for the quarter ending 2022-12-31 was $5.38M, a 15.62% increase year-over-year.
- Beam Therapeutics Inc. operating lease, cost for the quarter ending 2022-09-30 was $5.31M, a 16.44% increase year-over-year.
- Beam Therapeutics Inc. operating lease, cost for the quarter ending 2022-06-30 was $4.47M, a 2.06% decline year-over-year.
- Beam Therapeutics Inc. operating lease, cost for the quarter ending 2022-03-31 was $4.39M, a 3.77% decline year-over-year.
- Beam Therapeutics Inc. operating lease, cost for fiscal 2025 was $21.31M, a 1.56% decline from fiscal 2024.
- Beam Therapeutics Inc. operating lease, cost for fiscal 2024 was $21.65M, a 1.88% decline from fiscal 2023.
- Beam Therapeutics Inc. operating lease, cost for fiscal 2023 was $22.06M, a 12.94% increase from fiscal 2022.
- Beam Therapeutics Inc. operating lease, cost for fiscal 2022 was $19.54M, a 6.70% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $21.31M 10-K · filed 2026-02-24 | ||||
| 2024-12-31 | $21.65M 10-K · filed 2026-02-24 | ||||
| 2023-12-31 | $22.06M 10-K · filed 2026-02-24 | ||||
| 2022-12-31 | $5.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $10.68M derived: sum of 2 quarters · filed 2025-02-25 | $15.15M derived: sum of 3 quarters · filed 2025-02-25 | $19.54M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $5.31M 10-Q · filed 2022-11-07 | $9.78M derived: sum of 2 quarters · filed 2022-11-07 | $14.16M 10-Q · filed 2022-11-07 | $18.81M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $4.47M 10-Q · filed 2022-08-09 | $8.86M 10-Q · filed 2022-08-09 | $13.50M derived: sum of 3 quarters · filed 2024-02-27 | $18.06M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $4.39M 10-Q · filed 2022-05-09 | $9.04M derived: sum of 2 quarters · filed 2024-02-27 | $13.59M derived: sum of 3 quarters · filed 2024-02-27 | $18.16M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $4.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $9.21M derived: sum of 2 quarters · filed 2024-02-27 | $13.77M derived: sum of 3 quarters · filed 2024-02-27 | $18.31M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $4.56M 10-Q · filed 2022-11-07 | $9.12M derived: sum of 2 quarters · filed 2022-11-07 | $13.66M 10-Q · filed 2022-11-07 | $17.15M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $4.56M 10-Q · filed 2022-08-09 | $9.10M 10-Q · filed 2022-08-09 | $12.59M derived: sum of 3 quarters · filed 2023-02-28 | $14.23M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $4.56M 10-Q · filed 2022-05-09 | $8.03M derived: sum of 2 quarters · filed 2023-02-28 | $9.67M derived: sum of 3 quarters · filed 2023-02-28 | $11.38M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | $3.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $5.11M derived: sum of 2 quarters · filed 2023-02-28 | $6.82M derived: sum of 3 quarters · filed 2023-02-28 | $8.41M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $1.64M 10-Q · filed 2021-11-08 | $3.35M derived: sum of 2 quarters · filed 2021-11-08 | $4.95M 10-Q · filed 2021-11-08 | $4.95M 10-Q · filed 2020-11-10 | $6.41M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $1.71M 10-Q · filed 2021-08-10 | $3.30M 10-Q · filed 2021-08-10 | $4.76M derived: sum of 3 quarters · filed 2022-02-28 | $5.76M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | $1.60M 10-Q · filed 2021-05-11 | $3.06M derived: sum of 2 quarters · filed 2022-02-28 | $4.06M derived: sum of 3 quarters · filed 2022-02-28 | $4.97M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2019-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.46M derived: sum of 2 quarters · filed 2022-02-28 | $3.37M derived: sum of 3 quarters · filed 2022-02-28 | $4.08M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $1.00M 10-Q · filed 2020-11-10 | $1.91M derived: sum of 2 quarters · filed 2020-11-10 | $2.62M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $911.00K 10-Q · filed 2020-08-12 | $1.62M 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | $708.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |